Qube Research & Technologies (QRT)
STLN

Qube Research & Technologies (QRT)’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,642
Closed -$5.11K – 3825
2024
Q3 		$5.11K Hold
15,642
– – ﹤0.01% 3095
2024
Q2 		$7.2K Sell
15,642
-15,368
-50% -$13.1K ﹤0.01% 2989
2024
Q1 		$49K Buy
31,010
+14,558
+88% +$27.7K ﹤0.01% 3509
2023
Q4 		$33.6K Sell
16,452
-4,849
-23% -$8.41K ﹤0.01% 3396
2023
Q3 		$29.8K Sell
21,301
-49,217
-70% -$50.9K ﹤0.01% 3022
2023
Q2 		$38.8K Buy
+70,518
New +$37.3K ﹤0.01% 2097
2022
Q2 		– Sell
-37,850
Closed -$270K – 3125
2022
Q1 		$270K Buy
37,850
+19,162
+103% +$129K ﹤0.01% 1841
2021
Q4 		$182K Buy
+18,688
New +$166K ﹤0.01% 2004

Other funds holding STLN

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TAS
TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.62B AUM 18.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
QFA
Quattro Financial Advisors The Woodlands, Texas $468M AUM 13.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Qube Research & Technologies (QRT)'s STLN Position: Q4 2024 in Review

Qube Research & Technologies (QRT) sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2024, closing a stake of 15,642 shares — an estimated $5.11K sold.

Qube Research & Technologies (QRT) first reported a position in STLN in Q4 2021 and held it in 8 quarters. The position peaked at $270K in Q1 2022. 31 funds tracked by Wall St. Rank hold STLN as of Q4 2024.

  • Qube Research & Technologies (QRT) reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 15,642 Starling Oncology Institute, Inc. Common Stock shares in Q4 2024, an estimated $5.11K.
  • Qube Research & Technologies (QRT) first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Starling Oncology Institute, Inc. Common Stock position peaked at $270K in Q1 2022.
  • 31 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2024, filed 14 Feb 2025.